Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 351 results found since Jan 2013.
Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
Conclusion: This present study observed no difference in the efficacy and safety between biosimilar TNK and rTPA. Our findings are in concordance with published trials showing equivalence between the two molecules.
Source: Annals of Indian Academy of Neurology - January 25, 2023 Category: Neurology Authors: Ayush Mohan Snigdha Komakula Suhas Murali Pooja Anand Dyuti Shah VY Vishnu Awadh Kishor Pandit Ayush Agarwal Deepti Vibha Mamta Bhushan Singh MV Padma Srivastava Rohit Bhatia Source Type: research
Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System
CONCLUSION AND RELEVANCE: Conversion from alteplase to tenecteplase can be safely and effectively achieved at a large community hospital health system with differing levels of stroke certification. There were also additional cost savings and practical advantages including workflow benefits.PMID:36688289 | DOI:10.1177/10600280221149409
Source: The Annals of Pharmacotherapy - January 23, 2023 Category: Drugs & Pharmacology Authors: Erika Dittmar Thomas Wolfel Lourdes Menendez Jessilyn Pozo Maygret Ramirez Starlie C Belnap Felipe De Los Rios La Rosa Source Type: research
Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke
AbstractPurpose of ReviewTo review the current evidence and ongoing clinical trials evaluating the efficacy and safety of tenecteplase (TNK), an alternative tissue plasminogen activator (tPA), in the acute management of arterial ischemic stroke (AIS). To date, alteplase is the only tPA approved by the United States FDA for use in AIS.Recent FindingsThere have been multiple phase two and three trials investigating the safety and efficacy of TNK in AIS. In patients with AIS due to large vessel occlusion, one randomized controlled trial demonstrated superiority of TNK for vessel recanalization rates and long-term functional o...
Source: Current Treatment Options in Cardiovascular Medicine - January 2, 2023 Category: Cardiology Source Type: research
EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis
Alteplase is widely used as intravenous thrombolytic medication in acute ischemic stroke (AIS). However, tenecteplase, a genetically modified form of alteplase, has recently been shown to result in higher recanalization rates, improved functional outcome and a similar safety profile in AIS patients with large vessel occlusion (LVO) compared to alteplase. Accordingly, this study aims to evaluate the cost-effectiveness of 0.25mg/kg tenecteplase versus 0.9mg/kg alteplase for thrombolysis in AIS patients due to LVO from the Dutch healthcare payer perspective.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: C Nguyen, MMH Lahr, DJ Van der Zee, H Van Voorst, YBWEM Roos, M Uyttenboogaart, E Buskens Source Type: research
The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials
AbstractTenecteplase (TNK) is a promising candidate to replace alteplase as the standard of care for acute ischemic stroke (AIS); however, the optimal dosage is still to be investigated. Therefore, we aim to evaluate the safety and efficacy of TNK versus alteplase and to investigate the optimal TNK dosage. A systematic review, pairwise, and network meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, SCOPUS, EMBASE, and PubMed until July 26th, 2022. We used the risk ratio (RR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO w...
Source: Journal of Thrombosis and Thrombolysis - November 30, 2022 Category: Hematology Source Type: research
Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society
CONCLUSIONS: These expert consensus statements could provide a framework to guide the clinical decision-making process for the use of tenecteplase according to admission characteristics of AIS patients. However, existing data are limited, requiring inclusions in ongoing RCTs or real-life registries.PMID:36369068 | DOI:10.1016/j.neurol.2022.08.005
Source: Revue Neurologique - November 11, 2022 Category: Neurology Authors: S Olindo J-F Albucher Y Bejot J Berge C Cordonnier B Guillon D Sablot J Tardy S Alamowitch I Sibon Source Type: research
Combo Thrombolytic Approach Fails to Reduce ICH in Stroke Combo Thrombolytic Approach Fails to Reduce ICH in Stroke
The DUMAS study showed no benefit on the primary outcome of all ICH with low-dose alteplase followed by mutant pro-urokinase; but there were promising signs of a potential reduced bleeding risk.Medscape Medical News
Source: Medscape Cardiology Headlines - November 2, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
